PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First Line Chemotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chemotherapy Effect
- Metastatic Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
To evaluate the efficacy and safety of cendilizumab combined with bevacizumab in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) after first-line chemotherapy failure. The primary end point is objective response rate (ORR), the secondary end points are overall survival (OS), ...
To evaluate the efficacy and safety of cendilizumab combined with bevacizumab in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) after first-line chemotherapy failure. The primary end point is objective response rate (ORR), the secondary end points are overall survival (OS), progression-free survival (PFS), median time to response (MTTR), duration of response (DOR), adverse effects and quality of life.
Tracking Information
- NCT #
- NCT04872582
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Yanqun Xiang, Dr. Sun Yat-sen University
Get Well Soon